Elite in Relapsed Refractory Multiple Myeloma (RRMM)

Dr. David S. Siegel

General Practice | Emergency Medicine
18607 Ventura Blvd, Suite 302, 
Tarzana, CA 
Elite in Relapsed Refractory Multiple Myeloma (RRMM)
18607 Ventura Blvd, Suite 302, 
Tarzana, CA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

David Siegel is an Emergency Medicine provider in Tarzana, California. Dr. Siegel is rated as an Elite provider by MediFind in the treatment of Relapsed Refractory Multiple Myeloma (RRMM). His top areas of expertise are Relapsed Refractory Multiple Myeloma (RRMM), Smoldering Multiple Myeloma, T-Cell Lymphoma, and Vascular Birthmark.

His clinical research consists of co-authoring 218 peer reviewed articles and participating in 13 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 4 articles and participated in 2 clinical trials in the study of Relapsed Refractory Multiple Myeloma (RRMM).

Specialties
General Practice
Emergency Medicine
Licenses
Emergency Medicine in CA
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

LA Care
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO

Locations

18607 Ventura Blvd, Suite 302, Tarzana, CA 91356

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

13 Clinical Trials

Tandem Autologous Hematopoietic Stem Cell Transplant With Melphalan Followed by Melphalan and Bortezomib in Patients With Multiple Myeloma
Tandem Autologous Hematopoietic Stem Cell Transplant With Melphalan Followed by Melphalan and Bortezomib in Patients With Multiple Myeloma
Enrollment Status: Completed
Publish Date: September 17, 2025
Intervention Type: Drug
Study Drug: Bortezomib
Study Phase: Phase 3
Phase Ib-IIA Study of Combined Check Point Inhibition After Autologous Hematopoietic Stem Cell Transplantation in Patients at High Risk for Post-transplant Recurrence
Phase Ib-IIA Study of Combined Check Point Inhibition After Autologous Hematopoietic Stem Cell Transplantation in Patients at High Risk for Post-transplant Recurrence
Enrollment Status: Terminated
Publish Date: July 25, 2025
Intervention Type: Drug
Study Drugs: Ipilimumab, Nivolumab
Study Phase: Phase 1/Phase 2
A Phase I/II, Open-label, Dose Escalation and Expansion Study to Evaluate Safety, Tolerability, and Clinical Activity of the Antibody-Drug Conjugate GSK2857916 Administered in Combination With Lenalidomide Plus Dexamethasone (Arm A), or Bortezomib Plus Dexamethasone (Arm B) in Participants With Relapsed / Refractory Multiple Myeloma - DREAMM-6
A Phase I/II, Open-label, Dose Escalation and Expansion Study to Evaluate Safety, Tolerability, and Clinical Activity of the Antibody-Drug Conjugate GSK2857916 Administered in Combination With Lenalidomide Plus Dexamethasone (Arm A), or Bortezomib Plus Dexamethasone (Arm B) in Participants With Relapsed / Refractory Multiple Myeloma - DREAMM-6
Enrollment Status: Completed
Publish Date: March 18, 2025
Intervention Type: Drug
Study Drugs: Belantamab Mafodotin, Lenalidomide, Dexamethasone, Bortezomib
Study Phase: Phase 1/Phase 2
Prospective Multicenter Study to Measure the Impact of MMprofiler on Treatment Intention in Active Multiple Myeloma Patients
Prospective Multicenter Study to Measure the Impact of MMprofiler on Treatment Intention in Active Multiple Myeloma Patients
Enrollment Status: Active_not_recruiting
Publish Date: December 03, 2024
Intervention Type: Device
Study Phase: Not Applicable
Multicenter, Open-label, Single-arm, Phase 1b/2 Study of the Safety and Efficacy of Combination Treatment With Pomalidomide, Dexamethasone, and Carfilzomib (PdC) in Subjects With Relapsed and Relapsed/Refractory Multiple Myeloma
Multicenter, Open-label, Single-arm, Phase 1b/2 Study of the Safety and Efficacy of Combination Treatment With Pomalidomide, Dexamethasone, and Carfilzomib (PdC) in Subjects With Relapsed and Relapsed/Refractory Multiple Myeloma
Enrollment Status: Active_not_recruiting
Publish Date: November 19, 2024
Intervention Type: Drug
Study Drugs: Pomalidomide, Carfilzomib, Dexamethasone, Daratumumab
Study Phase: Phase 1/Phase 2
Phase I Study of Single-agent and Combined Checkpoint Inhibition After Allogeneic Hematopoietic Stem Cell Transplantation in Patients at High Risk for Post-transplant Recurrence
Phase I Study of Single-agent and Combined Checkpoint Inhibition After Allogeneic Hematopoietic Stem Cell Transplantation in Patients at High Risk for Post-transplant Recurrence
Enrollment Status: Terminated
Publish Date: November 18, 2024
Intervention Type: Drug
Study Drugs: Nivolumab, Ipilimumab
Study Phase: Phase 1
Protocol H125001: An Open-Label Phase 1/2 Study of JCARH125, BCMA-targeted Chimeric Antigen Receptor (CAR) T Cells, in Subjects With Relapsed or Refractory Multiple Myeloma
Protocol H125001: An Open-Label Phase 1/2 Study of JCARH125, BCMA-targeted Chimeric Antigen Receptor (CAR) T Cells, in Subjects With Relapsed or Refractory Multiple Myeloma
Enrollment Status: Completed
Publish Date: May 24, 2024
Intervention Type: Biological
Study Drugs: JCARH125, JCARH125 + Anakinra
Study Phase: Phase 1/Phase 2
(PRO#11307) Phase III Randomized Study of Autologous Stem Cell Transplantation With High-dose Melphalan Versus High-dose Melphalan and Bortezomib in Patients With Multiple Myeloma 65 Year or Older
(PRO#11307) Phase III Randomized Study of Autologous Stem Cell Transplantation With High-dose Melphalan Versus High-dose Melphalan and Bortezomib in Patients With Multiple Myeloma 65 Year or Older
Enrollment Status: Terminated
Publish Date: November 28, 2023
Intervention Type: Drug
Study Drugs: Melphalan, Bortezomib
Study Phase: Phase 2
A Phase I Open Label First in Human Dose Escalation of the Immunoproteasome Inhibitor M3258 as a Single Agent and Expansion Study of M3258 in Combination With Dexamethasone in Participants With Relapsed Refractory Multiple Myeloma
A Phase I Open Label First in Human Dose Escalation of the Immunoproteasome Inhibitor M3258 as a Single Agent and Expansion Study of M3258 in Combination With Dexamethasone in Participants With Relapsed Refractory Multiple Myeloma
Enrollment Status: Terminated
Publish Date: March 24, 2023
Intervention Type: Drug
Study Drugs: M3258, Dexamethasone
Study Phase: Phase 1
A Multi-Center Phase I/II, Open-Label, Dose-Finding Pilot Study of the Combination of Carfilzomib and Pomalidomide With Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
A Multi-Center Phase I/II, Open-Label, Dose-Finding Pilot Study of the Combination of Carfilzomib and Pomalidomide With Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
Enrollment Status: Terminated
Publish Date: August 01, 2022
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase II Study of Allogeneic Hematopoietic Stem Cell Transplantation for Multiple Myeloma Using a Conditioning Regimen of Fludarabine, Melphalan, and Bortezomib
A Phase II Study of Allogeneic Hematopoietic Stem Cell Transplantation for Multiple Myeloma Using a Conditioning Regimen of Fludarabine, Melphalan, and Bortezomib
Enrollment Status: Completed
Publish Date: May 25, 2022
Intervention Type: Drug
Study Phase: Phase 2
Phase 1 Study of SGN-CD352A in Patients With Relapsed or Refractory Multiple Myeloma
Phase 1 Study of SGN-CD352A in Patients With Relapsed or Refractory Multiple Myeloma
Enrollment Status: Terminated
Publish Date: August 12, 2019
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1, Dose-Escalation/Dose-Expansion Study Evaluating the Safety, Pharmacokinetics and Pharmacodynamic Effects of Orally Administered CB-5083 in Subjects With Lymphoid Hematological Malignancies
A Phase 1, Dose-Escalation/Dose-Expansion Study Evaluating the Safety, Pharmacokinetics and Pharmacodynamic Effects of Orally Administered CB-5083 in Subjects With Lymphoid Hematological Malignancies
Enrollment Status: Terminated
Publish Date: February 27, 2018
Intervention Type: Drug
Study Phase: Phase 1
View 12 Less Clinical Trials

218 Total Publications

Real-world outcomes of patients with relapsed refractory multiple myeloma treated with commercial bispecific T-cell engager antibodies: a single center experience.
Real-world outcomes of patients with relapsed refractory multiple myeloma treated with commercial bispecific T-cell engager antibodies: a single center experience.
Journal: Leukemia & lymphoma
Published: December 02, 2025
Similar Doctors
Experienced in Relapsed Refractory Multiple Myeloma (RRMM)
Dr. Jeffrey F. Wade
Emergency Medicine
Experienced in Relapsed Refractory Multiple Myeloma (RRMM)
Dr. Jeffrey F. Wade
Emergency Medicine

Andy Shen MD Inc

100 S Raymond Ave, 
Alhambra, CA 
 (23.2 miles away)
626-570-1606
Languages Spoken:
English
See accepted insurances

Jeffrey Wade is an Emergency Medicine provider in Alhambra, California. Dr. Wade is rated as an Experienced provider by MediFind in the treatment of Relapsed Refractory Multiple Myeloma (RRMM). His top areas of expertise are Febrile Neutropenia, Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL), Relapsed Refractory Multiple Myeloma (RRMM), and Smoldering Multiple Myeloma.

Experienced in Relapsed Refractory Multiple Myeloma (RRMM)
Dr. Allen S. Yang
Emergency Medicine
Experienced in Relapsed Refractory Multiple Myeloma (RRMM)
Dr. Allen S. Yang
Emergency Medicine

City Of Hope Medical Foundation

1500 Duarte Rd, 
Duarte, CA 
 (32.5 miles away)
626-256-4673
Languages Spoken:
English
See accepted insurances

Allen Yang is an Emergency Medicine provider in Duarte, California. Dr. Yang is rated as an Experienced provider by MediFind in the treatment of Relapsed Refractory Multiple Myeloma (RRMM). His top areas of expertise are Febrile Neutropenia, Chronic Inflammatory Response Syndrome (CIRS), Opioid Induced Constipation, Gallbladder Adenocarcinoma, and Bone Marrow Aspiration.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Siegel's expertise for a condition
ConditionClose
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile